Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.

McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.

Arch Intern Med. 2000 Jul 24;160(14):2185-91.

PMID:
10904462
2.

The efficacy and safety of sibutramine for weight loss: a systematic review.

Arterburn DE, Crane PK, Veenstra DL.

Arch Intern Med. 2004 May 10;164(9):994-1003. Review.

PMID:
15136309
3.

Sibutramine. A review of its contribution to the management of obesity.

McNeely W, Goa KL.

Drugs. 1998 Dec;56(6):1093-124. Review.

PMID:
9878996
4.

Modern medical management of obesity: the role of pharmaceutical intervention.

Aronne LJ.

J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. Review.

PMID:
9787732
5.
6.

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

Viner RM, Hsia Y, Tomsic T, Wong IC.

Obes Rev. 2010 Aug;11(8):593-602. doi: 10.1111/j.1467-789X.2009.00651.x. Epub 2009 Nov 17. Review.

PMID:
19922432
7.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
8.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
9.

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Davis R, Faulds D.

Drugs. 1996 Nov;52(5):696-724. Review.

PMID:
9118819
10.

Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.

Van Gaal LF, Wauters MA, De Leeuw IH.

Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:35-40. Review.

PMID:
9792480
11.

A benefit-risk assessment of sibutramine in the management of obesity.

Nisoli E, Carruba MO.

Drug Saf. 2003;26(14):1027-48. Review.

PMID:
14583064
12.

Sibutramine: a novel new agent for obesity treatment.

Ryan DH, Kaiser P, Bray GA.

Obes Res. 1995 Nov;3 Suppl 4:553S-559S. Review.

13.

Sibutramine--a review of clinical efficacy.

Lean ME.

Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S30-6; discussion 37-9. Review.

PMID:
9130039
14.

Pharmacological intervention: the antiobesity approach.

Rissanen A.

Eur J Clin Invest. 1998 Sep;28 Suppl 2:27-30. Review.

PMID:
9777325
15.

Cardiovascular risk-benefit profile of sibutramine.

Scheen AJ.

Am J Cardiovasc Drugs. 2010;10(5):321-34. doi: 10.2165/11584800-000000000-00000. Review.

16.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

17.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

18.

Sibutramine in overweight/obese hypertensive patients.

Sharma AM.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S20-3. Review.

PMID:
11916102
19.

Outcomes of pharmacological and surgical treatment for obesity.

Cerulli J, Malone M.

Pharmacoeconomics. 1998 Sep;14(3):269-83. Review.

PMID:
10186466
20.

[Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].

Astrup A.

Acta Med Austriaca. 1998;25(4-5):146-9. Review. German.

PMID:
9879391

Supplemental Content

Support Center